Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 4 1Phase 2 1Phase 1 1

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

NET 1Genitourinary 1Gastrointestinal 1Endocrine 1

Conditions

Prostatic Neoplasms 1Advanced Gastroenteropancreatic Neuroendocrine Tumor 1

Interventions

pembrolizumab 60Carboplatin 60Paclitaxel 51Magnetic Resonance Spectroscopy 42Specimen Handling 41Cisplatin 41Gemcitabine 34Bevacizumab 31Docetaxel 30Leucovorin 27Doxorubicin 27Fluorouracil 26Dexamethasone 25Cyclophosphamide 25Pemetrexed 23Radiotherapy 22Radiation 22Oxaliplatin 22Etoposide 21durvalumab 20Nivolumab 20Vincristine 19Taxes 19Rituximab 19Irinotecan 19Prednisone 18Letrozole 18Capecitabine 17Lenalidomide 16Immunoglobulin G 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Lutetium × 30 days × Clear all
NCT06520345 2026-05-27

The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

Telix Pharmaceuticals (Innovations) Pty Limited

Phase 3 Recruiting
520 enrolled
Genitourinary

Prostatic Neoplasms

NCT05884255 2026-05-19

An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Recruiting
220 enrolled
EndocrineGastrointestinalNET

Advanced Gastroenteropancreatic Neuroendocrine Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡